×
Trevena EBIT 2012-2024 | TRVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Trevena ebit from 2012 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Trevena EBIT 2012-2024 | TRVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Trevena ebit from 2012 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$140.4B
Bristol Myers Squibb (BMY)
$114.2B
Gilead Sciences (GILD)
$113.5B
Vertex Pharmaceuticals (VRTX)
$102.1B
CSL (CSLLY)
$83.7B
Regeneron Pharmaceuticals (REGN)
$77.8B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$37.8B
Alnylam Pharmaceuticals (ALNY)
$30.8B
BioNTech SE (BNTX)
$26.5B
Biogen (BIIB)
$21.5B
Illumina (ILMN)
$21.3B
BeiGene (BGNE)
$17B
Moderna (MRNA)
$15.2B
Genmab (GMAB)
$13.3B
Incyte (INCY)
$12.9B
Insmed (INSM)
$12.4B
BioMarin Pharmaceutical (BMRN)
$12.4B
Sarepta Therapeutics (SRPT)
$11.4B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$10.7B
Exact Sciences (EXAS)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.2B
QIAGEN (QGEN)
$10.1B
Exelixis (EXEL)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.9B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8.2B